A PYMNTS Company

France/ US: Cellectis in $1.6 billion Pfizer buyout talks

By  |  May 28, 2015

The specialists at Cellectis are considering a potential sale, and Pfizer is a likely buyer candidate according to the Financial Times.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The Financial Times is citing two people close to the situation who say the French biotech is in the early stages of negotiations. And one of the paper’s sources says Pfizer has stepped forward with an offer that would value Cellectis at as much as €1.5 billion.

    New York-based Pfizer declined comment to the FT.

     

    Full content: The Financial Times

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.